RE:RE:RE:RE:Musings about SP, PE multiple and JV contribution to same...Not that a $billion isn't enough, but when efficacy is proven with the thoroughness and safety we expect from TLT, I think (knowing nothing at all but willing to give my opinion :) that $200 million per indication may be on the low side. If the process works as expected and can be applied to various cancers, perhaps even without open surgery in the case of GBM, then the first 5 cancers will be just the tip of the iceberg and big pharma will know it. JV bidding war???
Quattro74 wrote: I'm imagining once we get to that point we will be a nasdaq and Toronto listed company. We might get some 'market forward looking boost'? We will have a higher sp to go along with the JV. I believe Bencro estimated $200M US per cancer indication, for research and development rights. Correct that we wont get a proper PE until we have that first product out. In 3 years time with a halt half way thru phase 2 and accelerated approval?? :-)
NorCalTommy wrote: Right, Sizzling, it would not be a PE per say (as there are no earnings), but regardless of whether a company makes a Billion in earnings or gets a cash infusion, i.e. JV or other financing, there should be a multiplier applied; I'm just not sure what that would be....
NCT